CBIO vs LDOS · $491.3M cap vs P/E 16, rev $16.66B
Crescent Biopharma, Inc. (CBIO) versus Leidos Holdings Inc (LDOS) — a side-by-side from cached financials, not a winner call.
Crescent Biopharma, Inc. (CBIO) is a biotechnology company listed on NASDAQ.
Leidos Holdings Inc (LDOS) is a information technology services company listed on US.
Latest reported CBIO revenue for 2026-06-30 was $0. Net income was -$24.8M. Revenue was down 100.0% from 2026-03-31 to 2026-06-30. CBIO currently screens at market cap $491.3M.
Latest reported LDOS revenue for 2025-01-03 was $16.66B. Net income was $1.25B. Revenue was up 7.9% from 2023-12-29 to 2025-01-03. LDOS currently screens at market cap $20.04B and trailing P/E 15.7.
CBIO currently screens at market cap $491.3M. LDOS currently screens at market cap $20.04B and trailing P/E 15.7.
Not investment advice. Open the CBIO and LDOS stock pages for the full models.
Not investment advice.